BlackRock Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

BlackRock Group’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$107K	Buy	783 +86	+12%	+$15.3K	﹤0.01%	2819
2016 Q3	$139K	Sell	697 -535	-43%	-$92.1K	﹤0.01%	2742
2016 Q2	$160K	Sell	1,232 -12	-1%	-$1.34K	﹤0.01%	2651
2016 Q1	$116K	Buy	1,244 +271	+28%	+$29.5K	﹤0.01%	2720
2015 Q4	$197K	Buy	973 +255	+36%	+$45.6K	﹤0.01%	2528
2015 Q3	$104K	Buy	+718	New	+$132K	﹤0.01%	2698

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

BlackRock Group's BLCM Position: Q4 2016 in Review

BlackRock Group increased its Bellicum Pharmaceuticals, Inc. (BLCM) stake by 12% in Q4 2016, buying an estimated $15.3K and bringing the position to 783 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #2819.

BlackRock Group first reported a position in BLCM in Q3 2015 and has held it in 6 quarters since. The position peaked at $197K in Q4 2015. 80 funds tracked by Wall St. Rank hold BLCM as of Q4 2016.

BlackRock Group held 783 shares of Bellicum Pharmaceuticals, Inc. worth $107K as of Q4 2016.
BlackRock Group bought 86 Bellicum Pharmaceuticals, Inc. shares in Q4 2016, an estimated $15.3K.
Bellicum Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2819 holding.
BlackRock Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and has held it in 6 quarters since.
BlackRock Group's Bellicum Pharmaceuticals, Inc. position peaked at $197K in Q4 2015.
80 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.